Purpose: The Y-box binding protein 1 () gene encodes the multifunctional protein YB1 that is associated with the dysregulation of numerous cancer-related genes. However, the prognostic value of and its correlation with immune cell infiltration in breast cancer (BRCA) remain unclear.
Methods: expression data in various malignancies were obtained from Oncomine, Tumor Immune Estimation Resource (TIMER), Cancer Cell Line Encyclopedia, UALCAN and cBio Cancer Genomics Portal databases. Survival data were analyzed with Kaplan-Meier plotter. Immune cell infiltration and its association with expression level were assessed with TIMER and LinkedOmics. YB1 expression was evaluated by immunohistochemistry and Western blotting, and changes in cancer cell viability and T cell activity following knockdown were assessed with an immunocyte-tumor cell co-culture assay.
Results: was downregulated in the BRCA cohort, which was closely associated with worse prognosis in the luminal A subtype (overall survival [OS]: hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.22-3.05, = 0.0042; recurrence-free survival [RFS]: HR 1.85, 95% CI 1.51-2.28, = 3.1e-9) and luminal B subtype (OS: HR 1.08, 95% CI 0.68-1.70, = 0.75; RFS: HR 1.29, 95% CI 1.02-1.62, = 0.03). expression was positively correlated with the M2 macrophage infiltration and expression of T cell exhaustion markers such as indoleamine 2,3-dioxygenase 1 () (rs = 0.388, = 4.93e-37) and cytotoxic T-lymphocyte-associated protein 4 () (rs = 0.321, = 2.54e-25) in luminal BRCA. Kaplan-Meier analysis revealed a correlation between expression, M2 infiltration and survival outcome. Co-culture with macrophages or T cells enhanced the decrease in luminal BRCA cell viability induced by knockdown.
Conclusion: High mRNA levels predict a poor prognosis in luminal BRCA, which is correlated with M2 macrophage infiltration and T cell exhaustion in the tumor microenvironment. Combining classic therapeutics with immune checkpoint inhibitors and M1 polarization agents may be an effective treatment strategy for luminal BRCA with overexpression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374538 | PMC |
| http://dx.doi.org/10.2147/CMAR.S311650 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deep Learning Predicts Subtype Heterogeneity and Outcomes in Luminal A Breast Cancer Using Routinely Stained Whole Slide Images.
Cancer Res Commun
December 2024
Indian Institute of Technology Bombay, Mumbai, Maharashtra, India.
Intratumor heterogeneity (ITH) presents challenges for precision oncology, but methods for its spatial quantification, scalable at population levels, do not exist. Based on previous work showing that admixture of PAM50 subtype can be measured from bulk tissue using transcriptomic data, we trained a deep neural network (DNN) to quantify subtype ITH in Luminal A (LumA) breast cancer from routinely-stained whole slide images. We tested the hypothesis that subtype admixture detected in images was associated with tumor aggressiveness and adverse outcome.
View Article and Find Full Text PDFFGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression.
Int J Cancer
December 2024
Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina.
Overcoming luminal breast cancer (BrCa) progression remains a critical challenge for improved overall patient survival. RUNX2 has emerged as a protein related to aggressiveness in triple-negative BrCa, however its role in luminal tumors remains elusive. We have previously shown that active FGFR2 (FGFR2-CA) contributes to increased tumor growth and that RUNX2 expression was high in hormone-independent mouse mammary carcinomas.
View Article and Find Full Text PDFAssessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics.
Lipids Health Dis
November 2024
Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.
Background: Resolvins, which are divided into series D (RvD) and E (RvE), originate from omega-3 fatty acids, DHA and EPA and were recently found to be involved in the modulation of inflammation in some tumors, including breast cancer (BC). We aimed to assess the resolvin profiles (RvD1, RvD2, RvD3 and RvE1) in the plasma of BC patients compared with those of controls and to determine differences in their concentrations according to BC presentation and immunohistochemical characteristics.
Methods: We considered BC patients (sporadic, familiar and BRCA1/2-mutated forms) naïve to any anticancer treatment and controls affected by nonmalignant breast disease.
Real-World Clinical Outcomes of Treatment With Olaparib for BRCA1/2 Mutation-Positive Metastatic Breast Cancer in Japanese Patients.
Cureus
October 2024
Department of Breast and Endocrine Surgery, Juntendo University Juntendo Hospital, Juntendo University School of Medicine, Tokyo, JPN.
Background Olaparib is effective in the treatment of metastatic breast cancer (MBC) patients, mainly confirmed by deleterious germline mutations. However, real-world data are scarce. Methodology A total of 10 cases from our institute and 17 cases from the relevant Japanese literature were reviewed.
View Article and Find Full Text PDFExpression of SIGLEC15 correlates with tumor immune infiltration, molecular subtypes, and breast cancer progression.
PLoS One
November 2024
Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, P. R. China.
Breast cancer (BRCA) is among the most prevalent cancers and is responsible for numerous patient fatalities. Immunotherapy has emerged as a promising approach to cancer treatment. Recent studies have identified Siglec-15 as a novel immune target that plays a crucial role in tumor immune evasion, suggesting its potential significance in BRCA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!